Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study
TORONTO, ON--(Marketwired - Nov 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after …